Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Acceptance and Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Vaccination in Systemic Sclerosis Patients Treated by Autologous Hematopoietic Stem Cell Transplantation

  • Read more about Acceptance and Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Vaccination in Systemic Sclerosis Patients Treated by Autologous Hematopoietic Stem Cell Transplantation

Novavax, Inc

By jpalfreyman on Tue, 07/25/2023 - 17:14
  • Read more about Novavax, Inc

Biosyngen Pte. Ltd.

By jpalfreyman on Fri, 07/21/2023 - 12:01
  • Read more about Biosyngen Pte. Ltd.

Egetis Therapeutics, Inc.

By jpalfreyman on Fri, 07/21/2023 - 11:23
  • Read more about Egetis Therapeutics, Inc.

PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19

  • Read more about PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19

An Intermediate Expanded Use Trial of DFMO

  • Read more about An Intermediate Expanded Use Trial of DFMO

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

  • Read more about A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

  • Read more about A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine

  • Read more about Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine

Multimodal Long Covid19

  • Read more about Multimodal Long Covid19

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 105
  • Page 106
  • Page 107
  • Page 108
  • Current page 109
  • Page 110
  • Page 111
  • Page 112
  • Page 113
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA